<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Crism Therapeutics Corporation — News on 6ix</title>
<link>https://6ix.com/company/crism-therapeutics-corporation</link>
<description>Latest news and press releases for Crism Therapeutics Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/crism-therapeutics-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d93de7d20c3ebdd60f016e.webp</url>
<title>Crism Therapeutics Corporation</title>
<link>https://6ix.com/company/crism-therapeutics-corporation</link>
</image>
<item>
<title>Positive Preclinical Data for Docetaxel ChemoSeed</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/positive-preclinical-data-for-docetaxel-chemoseed</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/positive-preclinical-data-for-docetaxel-chemoseed</guid>
<pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation announced positive preclinical data for its Docetaxel-ChemoSeed technology in a prostate cancer model, demonstrating significant anti-tumour activity and a favourable tolerability profile compared to standard systemic docetaxel. The study showed a 58% reduction in tumour volume at its most effective dose level, with a clear dose-response relationship and no adverse tolerability effects observed in ChemoSeed-treated groups, unlike the standard of care. These results</description>
</item>
<item>
<title>Board Changes</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/board-changes-491</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/board-changes-491</guid>
<pubDate>Thu, 02 Apr 2026 06:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation announces the resignation of Dr. Nermeen Varawalla from the Board of Directors, who served as Non-Executive Chair since the company's AIM listing in May 2024. Andrew Webb will continue as Interim Executive Chair while a search for a successor is underway, with Gerry Beaney taking over as Chair of the Remuneration Committee. The company expressed gratitude for Dr. Varawalla's contributions and noted that the search for a new Chair aligns with CRISM's progression tow</description>
</item>
<item>
<title>Phase 2 Clinical Trial Progress Update</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/phase-2-clinical-trial-progress-update</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/phase-2-clinical-trial-progress-update</guid>
<pubDate>Wed, 25 Mar 2026 07:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation has provided an update on its Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma, announcing that its contract manufacturer has successfully produced the first clinical batch of ChemoSeed. While the batch is undergoing final testing, the company is working with its contract research organisation and trial site to complete activation steps for patient dosing. Due to the ongoing site activation process, CRISM Therapeutics is extending its guidance for fi</description>
</item>
<item>
<title>Awarding of Orphan Drug Designation by the FDA</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/awarding-of-orphan-drug-designation-by-the-fda</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/awarding-of-orphan-drug-designation-by-the-fda</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation has received Orphan Drug Designation from the U.S. Food and Drug Administration for irinotecan in the treatment of malignant glioma, a designation that offers seven years of U.S. market exclusivity upon approval, tax credits for clinical trials, and fee exemptions. This regulatory milestone, following the UK's Innovation Passport for the ChemoSeed platform, significantly enhances the strategic and commercial profile of the irinotecan-ChemoSeed program, positioning </description>
</item>
<item>
<title>Japanese Patent Grant</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/japanese-patent-grant</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/japanese-patent-grant</guid>
<pubDate>Tue, 20 Jan 2026 07:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation has been granted patent number 7800909 by the Japanese Patent Office for its lead product, ChemoSeed, specifically relating to biodegradable chemotherapeutic drug implants containing irinotecan and their use in treating brain tumours like glioblastoma. This patent covers manufacturing processes and therapeutic applications, strengthening the company's intellectual property position in a key market and enhancing its appeal to potential commercial partners. CRISM The</description>
</item>
<item>
<title>Results of Shareholder Analysis</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/results-of-shareholder-analysis-2</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/results-of-shareholder-analysis-2</guid>
<pubDate>Fri, 09 Jan 2026 07:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of December 31, 2025, revealing significant holdings by Andrew Webb with 14.10%, Christopher McConville with 9.65%, Brian Murray with 9.49%, David Lawton with 9.28%, and Zeus Dynamic Opportunities Fund with 3.67%. Following recent share issuances, neither Linista Group Inc. nor Spreadex hold a disclosable stake. The company is preparing to initiate its registration-grade Phase 2 clinical t</description>
</item>
<item>
<title>Result of Retail Offer</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/result-of-retail-offer-55</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/result-of-retail-offer-55</guid>
<pubDate>Mon, 15 Dec 2025 14:29:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation has successfully raised gross proceeds of £59,610 through a retail offer of 662,332 shares at 9 pence per share. These funds, combined with those from a prior placing, will support the company's MHRA-approved Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients, with patient dosing expected in Q1 2026. The new Retail Offer Shares will be admitted to trading on the London Stock Exchange around December 16, 2025, bringing the total issued share ca</description>
</item>
<item>
<title>Retail Offer</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/retail-offer-46</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/retail-offer-46</guid>
<pubDate>Wed, 10 Dec 2025 07:25:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation is undertaking a retail offer to raise up to £100,000 by issuing new ordinary shares at 9 pence per share, with admission expected on December 16, 2025. This offer, alongside a separate placing, aims to fund the company's MHRA-approved Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients. The retail offer is exclusively for eligible investors in the United Kingdom and is conditional on the completion of the placing.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/holdings-in-company-1388</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/holdings-in-company-1388</guid>
<pubDate>Thu, 27 Nov 2025 07:00:00 GMT</pubDate>
<description>Spreadex LTD has notified CRISM Therapeutics Corporation that its total voting rights have decreased to 2.941200% as of November 19, 2025, down from a previous holding of 3.128900%. This change is due to an acquisition or disposal of voting rights, with Spreadex LTD now holding 1,175,000 direct voting rights attached to shares and 374 voting rights through financial instruments, totaling 1,175,374 voting rights.
Disclaimer*</description>
</item>
<item>
<title>US Orphan Drug Designation Application</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/us-orphan-drug-designation-application</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/us-orphan-drug-designation-application</guid>
<pubDate>Thu, 30 Oct 2025 07:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation has submitted an application to the FDA for Orphan Drug Designation for its Irinotecan-ChemoSeed™ to treat glioblastoma, a rare brain cancer affecting fewer than 200,000 patients in the US. If granted, the designation would provide benefits including seven years of US market exclusivity, tax credits for clinical research, and waiver of FDA application fees. CRISM has already been awarded an Innovation Passport in the UK and is exploring participation in Project Orb</description>
</item>
<item>
<title>Positive Preclinical Data in Prostate Cancer</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/positive-preclinical-data-in-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/positive-preclinical-data-in-prostate-cancer</guid>
<pubDate>Tue, 14 Oct 2025 06:00:00 GMT</pubDate>
<description>CRISM Therapeutics announced positive preclinical data for its ChemoSeed platform in prostate cancer, demonstrating that sustained docetaxel administration killed 72% of prostate cancer cells, compared to 65% with intermittent dosing. The concentration of docetaxel needed to inhibit 50% of prostate cancer cells was 3.5nM for sustained administration versus 9.8nM for intermittent dosing. The company also successfully formulated docetaxel within the ChemoSeed platform, achieving sustained drug rel</description>
</item>
<item>
<title>Half Year Report</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/half-year-report-829</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/half-year-report-829</guid>
<pubDate>Mon, 15 Sep 2025 06:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation announced its unaudited half-year results for the six months ended June 30, 2025, reporting a loss for the period of £930,000. Administration expenses totaled £905,000, including £357,000 in research and development. As of June 30, 2025, the company's cash reserves stood at £349,000. Subsequent to the period, in July 2025, CRISM raised £874,021 through a placing and retail offer. The company was also awarded an Innovate UK Launchpad grant of £96,106. Net cash at Se</description>
</item>
<item>
<title>Notice of Interim Results and IMC Presentation</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/notice-of-interim-results-and-imc-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/notice-of-interim-results-and-imc-presentation</guid>
<pubDate>Fri, 12 Sep 2025 06:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation will announce its Interim Results for the six months ended June 30, 2025, on Monday, September 15, 2025. Following the announcement, a live presentation will be hosted via Investor Meet Company on Tuesday, September 16, 2025, at 12.00pm BST. The presentation will include a discussion of the company's upcoming Phase 2 trial of irinotecan-ChemoSeed in glioblastoma, with the Phase 2 clinical trial expected to begin in Q1 2026. The Investor Meet Company presentation is</description>
</item>
<item>
<title>Approval for phase 2 clinical trial</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/approval-for-phase-2-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/approval-for-phase-2-clinical-trial</guid>
<pubDate>Mon, 01 Sep 2025 06:00:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and a favorable ethical opinion from a UK Research Ethics Committee to begin its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. The open-label trial is set to commence across selected UK clinical sites in Q1 2026. The study will assess the safety, tolerability, and efficacy of irinotecan-ChemoSeed, whic</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/result-of-agm-1301</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/result-of-agm-1301</guid>
<pubDate>Tue, 26 Aug 2025 15:03:00 GMT</pubDate>
<description>CRISM Therapeutics Corporation announced the results of its Annual General Meeting held on August 26, 2025, where all resolutions were duly passed. Resolutions 1, 3, 4, 5, 6, and 7 each received 5,094,571 votes for, representing 100.00% support, with 62 abstentions for all but resolution 6, which had 74. Resolutions 2, 8, 9, and 10 each received 5,094,049 votes for, representing 99.99% support, and 572 votes against, representing 0.01%, with 74 abstentions for resolution 2 and 12 for resolutions</description>
</item>
<item>
<title>GMP Manufacture of ChemoSeed</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/gmp-manufacture-of-chemoseed</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/gmp-manufacture-of-chemoseed</guid>
<pubDate>Tue, 12 Aug 2025 06:00:00 GMT</pubDate>
<description>GMP Manufacture of ChemoSeed.</description>
</item>
<item>
<title>Notice of AGM and EMI Option Plan</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/notice-of-agm-and-emi-option-plan</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/notice-of-agm-and-emi-option-plan</guid>
<pubDate>Mon, 04 Aug 2025 16:45:00 GMT</pubDate>
<description>Notice of AGM and EMI Option Plan.</description>
</item>
<item>
<title>Result of Retail Offer and Additional Placing</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/result-of-retail-offer-and-additional-placing</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/result-of-retail-offer-and-additional-placing</guid>
<pubDate>Thu, 03 Jul 2025 06:00:00 GMT</pubDate>
<description>Result of Retail Offer and Additional Placing.</description>
</item>
<item>
<title>Update presentation on the IMC platform</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/update-presentation-on-the-imc-platform</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/update-presentation-on-the-imc-platform</guid>
<pubDate>Tue, 01 Jul 2025 15:41:00 GMT</pubDate>
<description>Update presentation on the IMC platform.</description>
</item>
<item>
<title>Placing</title>
<link>https://6ix.com/company/crism-therapeutics-corporation/news/placing-33</link>
<guid isPermaLink="true">https://6ix.com/company/crism-therapeutics-corporation/news/placing-33</guid>
<pubDate>Mon, 30 Jun 2025 06:00:00 GMT</pubDate>
<description>Placing.</description>
</item>
</channel>
</rss>